Difference between revisions of "Quantal"

From Adonia Project
Jump to: navigation, search
(History)
 
Line 29: Line 29:
 
Quantal was founded by Yohan Lokensar after his departure from the cancer research lab of the  University of Kankadadka in 2011. Lokensar originally founded the company in Kankadadka but was forced to move his operations to Sabia as the University of Kankadadka launched an investigation on possible intellectual property violations. The investigation was dropped in 2013, citing lack of evidence.
 
Quantal was founded by Yohan Lokensar after his departure from the cancer research lab of the  University of Kankadadka in 2011. Lokensar originally founded the company in Kankadadka but was forced to move his operations to Sabia as the University of Kankadadka launched an investigation on possible intellectual property violations. The investigation was dropped in 2013, citing lack of evidence.
  
Quantal in the meantime had continued to expand, working on three sets of immunotherapy programs that attempted to tackle [[wikipedia: pancreatic cancer| pancreatic]], [[wikipedia:breast cancer|breast]] and [[wikipedia:liver|liver]] cancer. These programs utilized a variety of pharmaceutical products including three in-home developed products. Later in 2015 the company had listed on the [[Koblenz Stock Exchange]].
+
Quantal in the meantime had continued to expand, working on three sets of immunotherapy programs that attempted to tackle [[wikipedia: pancreatic cancer| pancreatic]], [[wikipedia:breast cancer|breast]] and [[wikipedia:liver|liver]] cancer. These programs utilized a variety of pharmaceutical products including three in-house developed products. Later in 2015 the company had listed on the [[Koblenz Stock Exchange]].
  
 
In 2019, Quantal released a report detailing a success in curing [[wikipedia:Triple-negative breast cancer|triple-negative breast cancer]] in a set of patients. In November of that year Lokensar stepped down as CEO after being listed as a sanctioned individual by [[Burawa]] under the [[Maya Losaxa]] strategy.
 
In 2019, Quantal released a report detailing a success in curing [[wikipedia:Triple-negative breast cancer|triple-negative breast cancer]] in a set of patients. In November of that year Lokensar stepped down as CEO after being listed as a sanctioned individual by [[Burawa]] under the [[Maya Losaxa]] strategy.

Latest revision as of 16:20, 15 January 2020

Quantal
Public
Traded as KSEQTL
Industry Pharmaceutics
Biotechnology
Founded February 11, 2011; 8 years ago (2011-02-11)
Founder Yohan Lokensar
Headquarters Khabale, Sabia
Key people
Karti Arenha (CEO),
Number of employees
200
Website quantal.com


Quantal is a immunotherapy company based in Khabale, Sabia. The company was founded by Yohan Lokensar, a prominent cancer researcher from the University of Kankadadka in Burawa. The company produces clinical-trial stage immunotherapy programs for pancreatic and breast cancer.

History

Quantal was founded by Yohan Lokensar after his departure from the cancer research lab of the University of Kankadadka in 2011. Lokensar originally founded the company in Kankadadka but was forced to move his operations to Sabia as the University of Kankadadka launched an investigation on possible intellectual property violations. The investigation was dropped in 2013, citing lack of evidence.

Quantal in the meantime had continued to expand, working on three sets of immunotherapy programs that attempted to tackle pancreatic, breast and liver cancer. These programs utilized a variety of pharmaceutical products including three in-house developed products. Later in 2015 the company had listed on the Koblenz Stock Exchange.

In 2019, Quantal released a report detailing a success in curing triple-negative breast cancer in a set of patients. In November of that year Lokensar stepped down as CEO after being listed as a sanctioned individual by Burawa under the Maya Losaxa strategy.

Therapies and Products

IL-15 superagonist, "Kayoor"

Kayoor is a superagonist that targets and improves cytokine interleukin-15 in the human body. The medicine was developed in late 2015 and is being used in clinical trials since 2017 after approval by the Medical Board of Sabia.

Pancreatic Cancer Therapy

Quantal's primary focus on Pancreatic Cancer therapy has continued to produce fruitful results with partial recoveries in most patients and full recovery in others.

Breast Cancer Therapy

As of 2019, Qantal's latest breast cancer therapy has resulted in a 100% success rate within clinical trials for Triple-negative breast cancer. The therapy is continuing to go under trials to assure success from remissions.

Prostate Cancer Therapy

Qantal's foray into prostate cancer therapy has been minimally reported as it has begun research in 2016. Clinical trials for this therapy would begin in 2020.